Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

POSTERS (1)59MULTIPOLAR CONTACT MAPPING GUIDED ABLATION OF TEMPORALLY STABLE HIGH FREQUENCY AND COMPLEX FRACTIONATED ATRIAL ELECTROGRAM SITES IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION60INTRA-CARDIAC AND PERIPHERAL LEVELS OF BIOCHEMICAL MARKERS OF FIBROSES IN PATIENTS UNDERGOING CATHETER ABLATION FOR ATRIAL FIBRILATION61THE DON'T WAIT TO ANTICOAGULATE PROJECT (DWAC) BY THE WEST OF ENGLAND ACADEMIC HEALTH SCIENCE NETWORK (AHSN) OPTIMISES STROKE PREVENTION FOR PATIENTS WITH ATRIAL FIBRILLATION (AF) WITHIN PRIMARY CARE IN LINE WITH NICE CG180 IN THE WEST OF ENGLAND62ILLNESS AND TREATMENT REPRESENTATIONS, COPING AND DISTRESS: VICIOUS CYCLES OF EVERYDAY EXPERIENCES IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION63THE NEEDS OF THE ADOLESCENT LIVING WITH AN INHERITED CARDIAC CONDITION: THE PATIENTS' PERSPECTIVE64SAFETY AND EFFICACY OF PARAMEDIC TREATMENT OF REGULAR SUPRAVENTRICULAR TACHYCARDIA (PARA-SVT)65NATURAL PROGRESSION OF QRS DURATION FOLLOWING IMPLATABLE CARDIOVERTER DEFIBRILLATORS (ICD) - IMPLANTATION66COMPARISON OF EFFICACY OF VOLTAGE DIRECTED CAVOTRICUSPID ISTHMUS ABLATION USING MINI VS CONVENTIONAL ELETRODES67CRYOBALLOON ABLATION (CRYO) FOR ATRIAL FIBRILLATION (AF) CANNOT BE GUIDED BY TEMPERATURE END-POINTS ALONE68MODERATOR BAND ECTOPY UNMASKED BY ADENOSINE AS A CAUSE OF ECTOPIC TRIGGERED IDIOPATHIC VF69EARLY CLINICAL EXPERIENCE WITH TARGETED SITE SELECTION FOR THE WiCS-LV ELECTRODE FOR CRT70DOES VECTOR MAPPING PRIOR TO IMPLANTABLE LOOP RECORDER INSERTION IMPROVE THE DETECTION OF ARRHYTHMIA?71THE ROLE OF SPECKLE TRACKING STRAIN IMAGING IN ASSESSING LEFT VENTRICULAR RESPONSE TO CARDIAC RESYNCHRONISATION THERAPY IN RESPONDERS AND NON-RESPONDERS72EVALUATING PATIENTS' EXPERIENCE AND SATISFACTION OF THE ATRIAL FIBRILLATION ABLATION PROCEDURE: A RETROSPECTIVE ANALYSIS73TROUBLESHOOTING LV LEAD IMPLANTATION - NOVEL 'UNIRAIL TECHNIQUE'74SUBCLINICAL ATHEROSCELEROSIS AND COGNITIVE IMPAIRMENT75EFFECT OF LOZARTANE ON DEVELOPMENT OF THE ELECTRICAL INSTABILITY OF THE MYOCARDIUM76THE INTERPLAY BETWEEN BODY COMPOSITION AND LEFT VENTRICULAR REMODELLING IN CARDIAC RESYNCHRONISATION THERAPY77FAMILY SCREENING IN IDIOPATHIC VENTRICULAR FIBRILLATION78MANAGEMENT OF ATRIAL FIBRILLATION IN A LARGE TEACHING HOSPITAL79THE EFFECT OF LEFT VENTRICULAR LEAD POSITION ON SURVIVAL IN PATIENTS WITH BINVENTRICULAR PACEMAKRS/DEFIBRILLATORS80ACUTE DEVICE IMPLANT-RELATED COMPLICATIONS DO NOT INCREASE LATE MORTALITY81ABORTED CARIDAC ARREST AS THE SENTINEL PRESENTATION IN A COHORT OF PATIENTS WITH THE CONCEALED BRUGADA PHENOTYPE82POST-CARDIAC DEVICE IMPLANTATION MOBILISATION ADVICE: A NATIONAL SURVEY83DO RISK SCORES DEVELOPED TO PROTECT ONE-YEAR MORTALITY ACTUALLY HELP IN ACCURATELY SELECTING PATIENTS RECEIVING PRIMARY PREVENTION ICD?84ATRIAL TACHYCARDIA ARISING FROM THE NON-CORONARY AORTIC CUSP85THE EFFECT OF DIFFERENT ATRIAL FIBRILLATION ABLATION STRATEGIES ON SURFACE ECG P WAVE DURATION86PRESCRIBING DRONEDARONE: HOW IS IT DONE ACROSS THE UK AND IS IT SAFE?87A CASE OF WIDE COMPLEX TACHYCARDIA88TRANSITION TO DEDICATED DAY CASE DEVICES - SAFETY AND EFFICACY IN A LARGE VOLUME CENTRE89SEQUENTIAL REGIONAL DOMINANT FREQUENCY MAPPING DURING ATRIAL FIBRILLATION: A NOVEL TEQUNIQUE90ELECTIVE CARDIOVERSION ENERGY PROTOCOLS: A RETROSPECTIVE COMPARISON OF ESCALATION STRATEGIES91THE INCIDENCE OF CLINCALLY RELEVANT HAEMATOMAS WITH PERIOPERATIVE USE OF NEWER P2Y12 INHIBITORS AND INTERRUPTED NOAC THERAPY IN CARDIAC IMPLANTABLE ELECTRONIC DEVICE INSERTION92AN AUDIT OF THE OUTCOMES FOR CHEMICAL AND DIRECT CURRENT CARDIOVERSION FOR ATRIAL FIBRILLATION AT OUR DGH OVER A 3 YEAR DURATION93REAL LIFE ACUTE MANAGEMET OF HAEMODYNAMICALLY TOLERATED MONOMORPHIC VENTRICULAR TACHYCARDIA. ARE WE MAKING EVIDENCE BASED ON DECISIONS?94A SERVICE EVALUATION TO ASSESS THE EFFICACY AND SAFETY OF NOVEL ORAL ANTICOAGULANTS VERSUS WARFARIN FOR ELECTIVE CARDIVERSION IN PATIENTS WITH NON VALVULAR AF IN A NURSE LED CARDIOVERSION SERVICE95PICK UP RATE OF IMPLANTED LOOP RECORDER AT A DISTRICT HOSPITAL

Autor: K. Nizam ud Din, T.E. Edwards, R.J. Taylor, A.S. Sadiq, A.Y. Yeoh, A.S. Moss, Hassan Shariat, S.V. Saravu Vijayashankar, E. Yones, G.O. Furniss, A. Merghani, S.A. Akbar, G. Collins, Bode Ensam, K. Al-Lawati, M. Shah, S. Honarbakhsh, C.J. McAloon, N.V. Getman, Sevara Tairova, A.A. Khokhar, D. Thomas, K. Prakash, D.E. Thomas, A. Opel, Aaisha Opel, D.P. Redfearn, Wern Yew Ding, Shohreh Honarbakhsh, R.T. Buck, E.C. Taylor, J. Moore, G.A. Begg, D.T. Raine, P. Langley, E.J. Shepherd, S. Murray, S.W. Lord, J.P. Bourke, S. Plein, G.Y. Lip, M. H. Tayebjee, N. Owen, S. White, M. O'Neill, L.D. Hughes, S. Carroll, R. Moss-Morris, V. Baker, C. Kirkby, K. Patel, G. Robinson, S. Antoniou, L. Richmond, W. Ullah, R.J. Hunter, M. Finlay, M.J. Earley, M. Whitbread, R.J. Schilling, R. Cooper, S. Modi, R. Somani, A. Ng, N. Hobson, J.C. Caldwell, S. Hadjivassilev, R. Ang, M. Dhinoja, M. Earley, S. Sporton, R. Schilling, R. Hunter, P. Lambiase, A.J. Turley, N.M. Child, N.J. Linker, W.A. Owens, S.A. James, J. Milner, M. Tayebjee, J. Sibley, A. Griffiths, T. Meredith, Y. Basher, T.R. Betts, K. Rajappan, P.D. Lambiase, M.D. Lowe, Gulnara Rakhimbaeva, Nigora Akramova, T.V. Getman, T. Hamborg, J.P. O'Hare, H. Randeva, F. Osman, N. Srinivasan, E. Firman, L. Tobin, C. Murphy, M. Lowe, P. Mohan, G. Salahia, H.S. Lim, HS Lim, Velislav Batchvarov, Paul Brennan, Andrew Cox, Alison Muir, Elijah Behr, S. Hamill, C. Laventure, S. Newell, B. Gordon, K. Bashir, J. Chuen, W. Foster, S. Yusuf, S. Hayat, D. Panagopoulos, E.J. Davies, D.R. Tomlinson, G.A. Haywood, J. Mullan, N. Kelland, A. Horwood, N. Connell, S. Odams, J. Maloney, A. Shetty, A. Kyriacou, J. Sahu, J. Lee, O.U. Uzun, A.W. Wong, S.A. Ashtekar, Javad Hashemi, Saeed Gazor, Damian Redfearn, A. Song, J. Jenkins, J. Glancy, D.W. Wilson, E.S. Sammut, I.D. Diab, T.R.C. Cripps, A.G. Gill, S.A. Abbas, J.U. Enye, A.W. Wahab, S.E. Elshafie, K.L. Ling, P.C. Carey, D.C. Chatterjee, S.T. Timbrell, W.T. Tufail, H.W. Why, R.M. Martos, A.R. Thornley, S. James, M.G.D. Bates, E.H. Hassan, J.Q. Quick, R.P.W. Cowell, E. Ho

Publikováno v: Europace. 18:ii24-ii35

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::589db54aa6af1fb9230eb04c213fb460
https://doi.org/10.1093/europace/euw273

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

147. Aberrant dopamine transporter function in kynurenine 3-monooxygenase knockout mice: Implications for psychosis

Autor: Jennifer M. Parrott, W.A. Owens, L.C. Daws, Jason C. O'Connor, D.J. Lodge, S. Perez, Abby M. Green, Laney Redus, J.N. Delgado

Publikováno v: Brain, Behavior, and Immunity. 40:e42-e43

Accumulating evidence implicates kynurenic acid, a modulator of glutamatergic and cholinergic neurotransmission, in the pathophysiology of schizophrenia and bipolar disorder. These neuropsychiatric disorders are associated with increased kynurenic ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::798a9858eed33bf7e2e30b537eae450c
https://doi.org/10.1016/j.bbi.2014.06.167

Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes

Autor: Michael P. Feneley, J. Michalicek, Z. Guan, H. Chaulet, Susan F. Steinberg, J Guo, Scott H. Kesteven, B.M. Mearns, W.A. Owens, F. Lin, Robert M. Graham, O.W. Prall

Publikováno v: Journal of molecular and cellular cardiology. 40(4)

We previously reported that transgenic (TG) mice with cardiac-restricted alpha(1A)-adrenergic receptor (alpha(1A)-AR)-overexpression showed enhanced contractility, but no hypertrophy. Since chronic inotropic enhancement may be deleterious, we investi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a5f1fe4921b76dcec1567d4f6bd98d
https://pubmed.ncbi.nlm.nih.gov/16516910